Recent Updates
Recently added Catalysts

Diclofenac diethylamine 2.32%

Phase 3

Pain | Small molecule | Pain |GSK plc|Last Updated: Apr 12, 2022

Target and mechanism

ModalitySmall molecule

Also known as Diclofenac diethylamine 2.32% gel

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment313

FDA Designations

No designations recorded

Clinical trial landscape

Diclofenac diethylamine 2.32% · 1 trial · 1 indication

Phase 3 1
NCT04052620Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority StudyPain
COMPLETED313 Analytics
PHASE3COMPLETED
Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study
PainUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Pain on Movement (POM) on Day 5 of Treatment as Assessed by a 100 Millimeter (mm) Visual Analogue Scale (VAS)
Baseline and Day 5

The investigator performed a movement of the ankle and the pain assessment was done by the participant using a 100 mm VAS by describing ankle pain on movement. The POM was registered by the participant by drawing a perpendicular line on the 100 mm VAS with anchors at 0 = no pain and 100 = extreme pain. Higher scores indicate a worse outcome. Change from Baseline in POM was calculated by subtracting the Baseline value from the Day 5 value.

Secondary Endpoints

Number of Participants With Severity of Adverse Events (AEs) Following Dosing With Study Medication
up to 28 days following last administration of the study product (or last procedure)
Change From Baseline of POM on VAS on Day 3 and Day 8 of Treatment Assessed by 100 mm VAS
Baseline and Days 3 and 8
Change From Baseline in Tenderness as Measured by Pressure Algometry on Days 3, 5 and 8
Baseline and Days 3, 5 and 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Diclofenac diethylamine (DDEA) 2.32%/ Placebo gelEXPERIMENTALParticipants will receive 4 tubes, DDEA 2.32% gel and Placebo gel (2 each) and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm\^2). DDEA 2.32% gel will be applied in morning and late afternoon and Placebo gel will be applied in noon and late evening for 7 days.
DDEA 1.16% gelACTIVE_COMPARATORParticipants will receive 4 tubes of DDEA 1.16% gel and instructed to apply the gel 5 centimeter (cm) topically with the finger tips (for approximately 1 minute) on both sides of affected ankle on area of approximately 200 square centimeters (cm\^2) in morning, noon, late afternoon, and late evening for 7 days.

Interventions

NameTypeDescription
Diclofenac diethylamine 2.32% gelDRUGParticipants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Diclofenac diethylamine 1.16% gelDRUGParticipants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 four times daily for 7 days.
PlaceboOTHERParticipants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm\^2 two times daily for 7 days.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersYes
Study Sites14

Inclusion Criteria: * Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment will be performed. * A participant who is willing and able to comply with scheduled visits, treat...

Countries:China
Unlock Eligibility Criteria